专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014060594A1 PRODUCTION OF A HCMV BASED VACCINE IN HUMAN AMNIOCYTE CELL LINES 审中-公开
标题翻译：在人体细胞系中生产基于HCMV的疫苗
公开(公告)号：WO2014060594A1
公开(公告)日：2014-04-24
申请号：PCT/EP2013/071887
申请日：2013-10-18
申请人： CEVEC PHARMACEUTICALS GMBH
发明人： SCHIEDNER, Gudrun , PLACHTER, Bodo
IPC分类号： C07K14/005 , C12N7/00 , C12N7/04 , C12N15/86 , C12N7/02
CPC分类号： C07K14/005 , A61K39/00 , C12N7/00 , C12N15/86 , C12N2710/16123 , C12N2710/16134 , C12N2710/16151 , G01N33/56994 , G01N2333/045 , G01N2469/20
摘要： The present invention relates to a method for the production of human Cytomegalovirus (HCMV) particles, the method including the steps of: (a) contacting and thereby infecting a permanent human amniocyte cell with HCMV, (b) incubating the amniocyte cell, (c) allowing expression of HCMV particles, and (d) isolating of the HCMV particles, wherein the permanent human amniocyte cell expresses the adenoviral gene products E1A and E1B and wherein the amniocyte cells are cultured in serum free medium. Furthermore, the present invention relates to HCMV particles produced by the method of the present invention as well as to a HCMV based vaccine comprising the HCMV particles, the use of the HCMV particles for use in the preparation of a HCMV based vaccine and the HCMV particles for use in the preparation of a therapeutic or diagnostic agent for the prevention or treatment of a HCMV related disease.
摘要翻译：本发明涉及一种生产人巨细胞病毒（HCMV）颗粒的方法，所述方法包括以下步骤：（a）使HCMV接触并由此感染永久性人羊膜细胞，（b）孵育羊膜细胞，（c ），并且（d）分离HCMV颗粒，其中永久性人羊膜细胞表达腺病毒基因产物E1A和E1B，并且其中所述羊水细胞细胞在无血清培养基中培养。此外，本发明涉及通过本发明的方法制备的HCMV颗粒以及包含HCMV颗粒的基于HCMV的疫苗，使用HCMV颗粒用于制备基于HCMV的疫苗和HCMV颗粒用于制备用于预防或治疗HCMV相关疾病的治疗剂或诊断剂。

2. 发明申请

WO2004023091A3 LOCALIZATION OF HUMAN CYTOMEGALOVIRUS NUCLEIC ACIDS AND PROTEINS IN HUMAN CANCER CELLS 审中-公开
标题翻译：人类癌细胞中人体细胞核的核酸和蛋白质的定位
公开(公告)号：WO2004023091A3
公开(公告)日：2004-06-17
申请号：PCT/US0327403
申请日：2003-09-03
申请人： UAB RESEARCH FOUNDATION
发明人： COBBS CHARLES , HARKINS LUALHATI
IPC分类号： C12Q1/68 , C12Q1/70 , G01N33/53 , G01N33/569
CPC分类号： G01N33/56994 , C12Q1/6886 , C12Q1/705 , C12Q2600/112 , G01N2333/045
摘要： The present disclosure shows human cytomegalovirus (HCMV) is strongly associated with a variety of cancers in humans. In addition, the present disclosure shows a specific strain of HCMV, HDu, is associated with several types of cancer. The identification cells harboring certain strains of HCMV, such as HDu, will provide a novel mechanism to identify cells that are at risk for undergoing oncogenesis. Novel strategies for detecting HCMV are also disclosed.
摘要翻译：本公开显示人巨细胞病毒（HCMV）与人类中的各种癌症强烈相关。此外，本公开显示了HCMV的特异性菌株，HDu与几种类型的癌症相关。携带某些HCMV菌株的识别细胞，如HDu，将提供一种新型机制，以鉴定处于发生肿瘤发生风险的细胞。还公开了用于检测HCMV的新策略。

3. 发明申请

WO0216555A2 CELL LINES, THEIR PREPARATION AND USE 审中-公开
标题翻译：细胞系，其制备和使用
公开(公告)号：WO0216555A2
公开(公告)日：2002-02-28
申请号：PCT/GB0103726
申请日：2001-08-17
申请人： UNIV WALES MEDICINE , JONES CHRISTOPHER JOHN , KIPLING DAVID GLYN , WILKINSON GAVIN , MCSHARRY BRIAN , SKINNER JULIA WENDY
发明人： JONES CHRISTOPHER JOHN , KIPLING DAVID GLYN , WILKINSON GAVIN , MCSHARRY BRIAN , SKINNER JULIA WENDY
IPC分类号： C12N5/077 , G01N33/50 , G01N33/569 , C12N5/00
CPC分类号： G01N33/5044 , C12N5/0656 , C12N2503/00 , C12N2510/02 , C12N2510/04 , G01N33/5008 , G01N33/502 , G01N33/5091 , G01N33/56983 , G01N2333/045
摘要： An immortalised cell line is disclosed, which is suitable for use in vaccine production, characterised in that the cells thereof are adapted to express hTERT, the catalytic subunit of human telomerase. A suitable cell line comprises human diploid fibroblasts, such as those derivable from MRC-5 or WI38 cell lines, transfected with cDNA of hTERT or infected by a retrovirus carrying cDNA of hTERT, which transfected or infected cells are capable eof supporting antigen production. A method for preparing such cell lines, using recombinant techniques, is also disclosed. The cell lines may be used as a diagnostic test for the presence of a virus, such as HCMV, which assay method includes the step of (a): contacting a sample of the telomerase-immortalised cell line whose genome contains a nucleotide sequence comprising a reporter gene capable of causing a measurable response, which reporter gene is under the control of the virus promoter region whereby expression of the reporter protein corresponds to expression of the virus in the sample. Alternatively, the telomerase-immortalised cell lines may be used to determine the efficacy of anti-viral agents by testing the capability of a modified virus, such as HCMV containing a reporter gene, to infect these cells. The assay method includes the step of (a): contacting a sample of the telomerase-immortalised cells with the modified virus, whereby expression of the reporter protein corresponds to infection of the cells in the sample. Preferably, the methods further include the step of (b): measuring the response of the reporter; and/or (c) comparing the measurement resulting from step (b) with the response from a standard or non-immortalised sample, which has itself undergone assay method steps (a) and (b).
摘要翻译：公开了一种适用于疫苗生产的永生细胞系，其特征在于其细胞适于表达人类端粒酶的催化亚单位hTERT。合适的细胞系包括人二倍体成纤维细胞，例如衍生自MRC-5或WI38细胞系的那些，转染有hTERT的cDNA或被携带有hTERT的cDNA的逆转录病毒感染的转染或感染的细胞能够支持抗原产生。还公开了使用重组技术制备这种细胞系的方法。细胞系可用作病毒如HCMV的存在的诊断试验，该测定方法包括以下步骤：（a）：使端粒酶永生化细胞系的样品接触，其基因组含有包含报告基因能够引起可测量的反应，该报告基因处于病毒启动子区域的控制下，由此报道蛋白的表达对应于样品中病毒的表达。或者，端粒酶永生化细胞系可用于通过测试修饰的病毒（例如含有报告基因的HCMV）感染这些细胞的能力来测定抗病毒剂的功效。测定方法包括以下步骤：（a）：使端粒酶永生化细胞的样品与经修饰的病毒接触，由此报道蛋白的表达对应于样品中细胞的感染。优选地，所述方法还包括步骤（b）：测量报告者的反应; 和/或（c）将步骤（b）得到的测量与本身经过测定方法步骤（a）和（b）的标准或非永生化样品的响应进行比较。

4. 发明申请

WO1998022619A1 METAL MEDIATED SERINE PROTEASE INHIBITORS 审中-公开
标题翻译：金属调控丝氨酸蛋白酶抑制剂
公开(公告)号：WO1998022619A1
公开(公告)日：1998-05-28
申请号：PCT/US1997004450
申请日：1997-03-21
申请人： ARRIS PHARMACEUTICAL CORPORATION , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , CLARK, James, M. , ELROD, Kyle , JENKINS, Thomas, E. , KATZ, Bradley, A. , MOORE, William, R. , STROUD, Robert, M.
发明人： ARRIS PHARMACEUTICAL CORPORATION , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
IPC分类号： C12Q01/37
CPC分类号： C07D401/04 , C07D235/18 , C07D235/20 , C07D401/06 , C07D403/06 , C07K14/811 , C12N9/6424 , C12Q1/37 , G01N2333/045 , G01N2333/811 , G01N2333/96433 , G01N2333/976
摘要： The present invention relates to serine protease inhibitors having a P site binding moiety and a divalent cation(s) chelating moiety which are pre-prepared as divalent cation(s) complexes or combined with the serine protease in the presence of divalent cation(s) and methods for identifying and using the inhibitors. The compounds are shown to have high inhibitory activity when complexed to divalent cation(s) and are useful in various processes associated with serine protease isolation and inhibition.
摘要翻译：本发明涉及具有P位结合部分和二价阳离子螯合部分的丝氨酸蛋白酶抑制剂，其在二价阳离子存在下预先制备为二价阳离子配合物或与丝氨酸蛋白酶组合，和用于识别和使用该抑制剂的方法。示的化合物时络合二价阳离子（一个或多个），并且与丝氨酸蛋白酶的分离和抑制相关的各种处理有用的是具有高的抑制活性。

5. 发明申请

WO1990013667A1 IMPROVED AMPLIFIED NUCLEIC ACID HYBRIDIZATION ASSAYS FOR HBV 审中-公开
标题翻译：用于HBV的改良的放大核酸混合测定
公开(公告)号：WO1990013667A1
公开(公告)日：1990-11-15
申请号：PCT/US1990002049
申请日：1990-04-16
申请人： CHIRON CORPORATION
发明人： CHIRON CORPORATION , URDEA, Michael, S. , WARNER, Brian , RUNNING, Joyce, A. , KOLBERG, Janice, A. , CLYNE, Jennifer, M. , SANCHEZ-PESCADOR, Ray , HORN, Thomas
IPC分类号： C12Q01/68
CPC分类号： C07H19/06 , C07H21/00 , C12Q1/682 , C12Q1/689 , C12Q1/706 , G01N33/532 , G01N2333/045 , Y10S435/81
摘要： Amplified solution-phase sandwich nucleic acid hybridization assays for HBV in which (1) analyte is hybridized in solution with sets of amplifier probe oligonucleotides and capture probe oligonucleotides each having a first segment that is complementary to a consensus HBV ds region sequence based on a multiplicity of HBV subtypes and a second segment that is complementary to a unit of an oligonucleotide multimer and an oligonucleotide bound to a solid phase, respectively (2) the resulting product is reacted with the oligonucleotide bound to a solid phase (3), the resulting product is washed to remove unbound materials (4), the bound materials are reacted with the multimer (5), the bound materials are washed to remove unbound multimer (6), the bound materials are reacted with a labeled probe complementary to the oligonucleotide units of the multimer.
摘要翻译：针对HBV的扩增溶液相夹心核酸杂交测定法，其中（1）分析物在溶液中与一组放大器探针寡核苷酸和捕获探针寡核苷酸杂交，每个具有与基于多重性的共有HBV ds区序列互补的第一区段的HBV亚型和与寡核苷酸多聚体单元和与固相结合的寡核苷酸互补的第二区段（2）将所得产物与与固相（3）结合的寡核苷酸反应，得到的产物洗涤以除去未结合的物质（4），结合的物质与多聚体（5）反应，洗涤结合的物质以除去未结合的多聚体（6），结合的物质与与寡核苷酸单位互补的标记探针反应多聚体。

6. 发明申请

WO2017060912A1 METHODS AND KITS FOR PREDICTION AND DIAGNOSIS OF HUMAN CYTOMEGALOVIRUS CONGENITAL (hCMV) TRANSMISSION 审中-公开
标题翻译：用于人类胞质血凝素（hCMV）传递的预测和诊断的方法和工具
公开(公告)号：WO2017060912A1
公开(公告)日：2017-04-13
申请号：PCT/IL2016/051097
申请日：2016-10-09
申请人： GENEFRON LTD.
发明人： SMITH, Yoav
IPC分类号： C12Q1/68 , G01N33/50 , G06F19/20
CPC分类号： C12Q1/68 , C12Q1/6883 , C12Q2600/158 , G01N33/56994 , G01N2333/045 , G06F19/20
摘要： The present invention relates to methods and kits for the prediction and diagnosis of intrauterine-transmission of viral pathogens, specifically, hCMV in a mammalian subject, by calculating the ability of a subject to prevent transmission of said hCMV based on determining the expression of ISG15, IFIT3 and USP18 genes and optionally of EIF2AK2, HERC5, RSAD2 and MX1 genes in a sample of said subject.
摘要翻译：本发明涉及通过基于确定ISG15的表达来计算受试者防止所述hCMV传播的能力来预测和诊断病毒病原体（特别是哺乳动物受试者中的hCMV）的子宫内传播的方法和试剂盒， IFIT3和USP18基因以及任选的所述受试者样品中的EIF2AK2，HERC5，RSAD2和MX1基因。

7. 发明申请

WO2013148373A1 ANTI-HCMV IDIOTYPIC ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗HCMV抗体抗体及其用途
公开(公告)号：WO2013148373A1
公开(公告)日：2013-10-03
申请号：PCT/US2013/032661
申请日：2013-03-15
申请人： GENENTECH, INC. , F. HOFFMANN-LA ROCHE AG
发明人： HONGO, Jo-anne , XU, Keyang , MAIA, Mauricio , VIJ, Rajesh , WONG, Terence , LOWE, John , LI, Yanhong , LIU, Luna
IPC分类号： C07K16/42 , G01N33/68
CPC分类号： C07K16/4216 , C07K16/088 , C07K2317/56 , C07K2317/92 , G01N33/56994 , G01N33/686 , G01N2333/045 , G01N2469/20
摘要： The invention provides anti-idiotypic HCMV antibodies as well as methods of using the same.
摘要翻译：本发明提供抗独特型HCMV抗体及其使用方法。

8. 发明申请

WO2012156733A1 DETECTION AND DEPLETION OF HCMV INFECTED CELLS 审中-公开
标题翻译：检测和清除HCMV感染细胞
公开(公告)号：WO2012156733A1
公开(公告)日：2012-11-22
申请号：PCT/GB2012/051094
申请日：2012-05-16
申请人： CAMBRIDGE ENTERPRISE LIMITED , LEHNER, Paul , SINCLAIR, John , WEEKS, Michael , ANTROBUS, Philip
发明人： LEHNER, Paul , SINCLAIR, John , WEEKS, Michael , ANTROBUS, Philip
IPC分类号： G01N33/569 , G01N33/50 , G01N33/68 , A61L2/00 , A61K45/06
CPC分类号： G01N33/56994 , G01N33/5073 , G01N33/6893 , G01N2333/045 , G01N2500/00 , G01N2800/245
摘要： This invention relates to the identification and/or elimination of Human Cytomegalovirus (HCMV) infected cells from mammalian cell populations by determining the expression of multidrug resistance-associated protein-1 (MRP-1) and/or other UL138 modulated cell surface proteins. HCMV infected cells may be identified through alterations in the expression MRP-1 and/or other UL138 modulated cell surface proteins, and separated. Mammalian cell populations depleted of HCMV infected cells may be useful, for example in transplants, such as bone marrow transplants.
摘要翻译：本发明涉及通过确定多药耐药相关蛋白-1（MRP-1）和/或其他UL138调节的细胞表面蛋白的表达来鉴定和/或消除来自哺乳动物细胞群体的人巨细胞病毒（HCMV）感染的细胞。可以通过表达MRP-1和/或其他UL138调节的细胞表面蛋白质的改变来鉴定HCMV感染的细胞，并分离。耗尽HCMV感染细胞的哺乳动物细胞群可能是有用的，例如在移植物例如骨髓移植中。

9. 发明申请

WO2012141653A1 GENETIC VARIANT OF CYTOMEGALOVIRUS (CMV) 审中-公开
标题翻译： CYPEGEGEGOVIRUS（CMV）的遗传变异
公开(公告)号：WO2012141653A1
公开(公告)日：2012-10-18
申请号：PCT/SE2012/050407
申请日：2012-04-13
申请人： NAUCLÉR, Cecilia
发明人： NAUCLÉR, Cecilia
IPC分类号： C07K14/045 , G01N33/68
CPC分类号： C12N7/00 , C07K14/005 , C12N2710/16121 , C12N2710/16122 , C12N2800/24 , C12Q1/701 , G01N33/5091 , G01N33/56994 , G01N33/57407 , G01N2333/045 , G01N2800/50
摘要： The present invention relates to a genetic variant of CMV, said genetic variant lacking intron 2 of the IE region of CMV (CMV ΙΕΔi2). The present invention also related to various uses of this genetic variant as well as RNA splice variants transcribed therefrom, and proteins expressed from the RNA splice variants, such as in the diagnosis of a CMV related cancer disease, and identification of individuals at risk of developing cancer or risk of transferring the CMV ΙΕΔi2 virus with a human sample and prevention and treatment through targeting of unique CMV IE proteins for immunotherapy and vaccination.
摘要翻译：本发明涉及CMV的遗传变体，所述遗传变体缺乏CMV（CMV2i2）的IE区域的内含子2。本发明还涉及该遗传变异体的各种用途以及从其转录的RNA剪接变体，以及从RNA剪接变体表达的蛋白质，例如诊断CMV相关的癌症疾病，以及鉴定处于发展风险中的个体癌症或将CMV？i2病毒转染人类样本的风险，并通过靶向独特的CMV IE蛋白进行免疫治疗和疫苗接种来进行预防和治疗。

10. 发明申请

WO2012118388A1 PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN A FC-FUNCTION ASSAY 审中-公开
标题翻译：肽 - 脂肪结构及其在FC功能测定中的应用
公开(公告)号：WO2012118388A1
公开(公告)日：2012-09-07
申请号：PCT/NZ2012/000029
申请日：2012-03-05
申请人： KODE BIOTECH LIMITED , HENRY, Stephen Micheal , KOMARRAJU, Venkata Sarvani
发明人： HENRY, Stephen Micheal , KOMARRAJU, Venkata Sarvani
IPC分类号： G01N33/555 , C07K14/00 , C07F9/10 , C07K17/06 , G01N33/53 , G01N33/531 , G01N33/536 , C07K14/045 , G01N33/68 , A61K39/385 , A61K31/683 , A61K38/16
CPC分类号： G01N33/6854 , C07F9/65583 , C07K14/005 , C12N2710/16122 , G01N33/6857 , G01N2333/045 , G01N2333/4716
摘要： The present invention discloses a method of assaying Fc-function in an immunoglobulin containing sample by contacting the sample, in the presence of a complement, with red blood cells modified to incorporate a F-S-L peptide- lipid construct. The F-S-L peptide construct comprises a functional group (F) that is a target antigen for a complement activating immunoglobulin, a spacer group (S) covalently linking F to L and a lipid group (L). The present invention further discloses a specific construct, DOPE-Ad-CMG(2)-hCMV2 (see below) where the F group is an antigen of cytomegalovirus, that is used in assaying the Fc function of an intravenous immunoglobulin (IVIG) product.
摘要翻译：本发明公开了一种通过在补体存在下将样品与经修饰以掺入F-S-L肽 - 脂质构建体的红细胞接触来测定含免疫球蛋白的样品中的Fc功能的方法。 F-S-L肽构建体包含作为补体激活免疫球蛋白的靶抗原的官能团（F），共价连接F与L和脂质（L）的间隔基（S）。本发明还公开了特异性构建体，其中F基团是巨细胞病毒的抗原，用于测定静脉内免疫球蛋白（IVIG）产物的Fc功能的DOPE-Ad-CMG（2）-hCMV2（见下文）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式